Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,intangibleAssets,capitalSurplus,totalLiab,totalStockholderEquity,totalAssets,commonStock,retainedEarnings,otherLiab,treasuryStock,cash,totalCurrentLiabilities,otherStockholderEquity,totalCurrentAssets,accountsPayable,otherCurrentLiab,netReceivables,changeToLiabilities,totalCashflowsFromInvestingActivities,totalCashFromFinancingActivities,changeToOperatingActivities,issuanceOfStock,changeInCash,effectOfExchangeRate,totalCashFromOperatingActivities,depreciation,changeToNetincome,netBorrowings,WC,language,region,quoteType,triggerable,quoteSourceName,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,priceEpsCurrentYear,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,marketCap,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,esgPopulated,tradeable,currency,epsCurrentYear,market,shortName,exchange,marketState,priceHint,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,dividendDate,earningsTimestamp,earningsTimestampStart,exchangeDataDelayedBy,earningsTimestampEnd,gmtOffSetMilliseconds,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,"Shares Short (May 27, 2021) 4","Short Ratio (May 27, 2021) 4","Short % of Float (May 27, 2021) 4","Short % of Shares Outstanding (May 27, 2021) 4","Shares Short (prior month Apr 29, 2021) 4",Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,longBusinessSummary,city,phone,state,compensationAsOfEpochDate,country,website,maxAge,address1,industry,address2
t0,ENVB,16629501.0,21390300,157952,,-3250711,,-3250711,6607045,0,-6764997,-6764997,,,,,,0,0,6764997,0,3514286,,-3250711,-3250711,2362177.0,33952988.0,6794947.0,18991678.0,25786625.0,194499.0,-15010268.0,6168000.0,-145541.0,22657150.0,626947.0,-145541.0,23424448.0,626947.0,,,-59278.0,-675000.0,24881733.0,-66208.0,24881733.0,21078690.0,34235.0,-3162278.0,136640.0,77279.0,,22797501.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,2.0701,1630509439,0.08010006,2.05,2.14,2.01,796799,-3.2858732,1.9122223,0.1578778,0.08256248,2.5469565,-0.47685647,-0.187226,44280060,15,America/New_York,EDT,False,False,USD,-0.63,us_market,"Enveric Biosciences, Inc.",NCM,REGULAR,4,4.0251284,2.01 - 2.14,1.99,2.09,2.1,11,8,finmb_650902272,NasdaqCM,"Enveric Biosciences, Inc.",USD,1124845,409050,0.59010005,0.39871624,1.48 - 15.04,-12.9699,-0.86236036,1.48,15.04,1574640000,1621323004,1628765940,0,1629115200,-14400000,,,,15.04,1.48,1.9122,2.547,1.12M,409.05k,21.39M,,16.85M,25.53%,5.24%,1.06M,0.39,5.55%,4.95%,536.9k,,,,,,0.00%,"Nov 24, 2019","Apr 22, 2008",,,"Dec 30, 2020","Mar 30, 2021",0.00%,0.00%,-55.15%,-110.38%,,,,,,-9.02M,,,22.66M,1.06,,,37.36,,-6.16M,-2.91M,Value,34103,Healthcare,2,"Enveric Biosciences, Inc., a pharmaceutical company, engages in developing various cannabinoid medicines for cancer care. It has a pipeline of development programs for radiodermatitis, glioblastoma multiforme, pruritus, rashes, and dry skin and chemotherapy-induced neuropathy. The company is headquartered in Naples, Florida.",Naples,239 302 1707,FL,1609372800,United States,http://www.enveric.com,86400,4851 Tamiami Trail North,Biotechnology,Suite 200
t-1,ENVB,1565166.0,21390300,174083,,-4382489,,-4382489,3349190,0,-3523273,-3523273,,-57107.0,,,,0,0,3523273,0,-859216,,-4382489,-4382489,1817721.0,15222770.0,681250.0,3382887.0,4096891.0,100951.0,-11759557.0,,-181277.0,1578460.0,681250.0,-181277.0,2279170.0,681250.0,,,267002.0,-44143.0,3599074.0,-636497.0,3372500.0,1237562.0,-67382.0,-2249987.0,120872.0,2092494.0,-33926.0,1597920.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,2.0701,1630509439,0.08010006,2.05,2.14,2.01,796799,-3.2858732,1.9122223,0.1578778,0.08256248,2.5469565,-0.47685647,-0.187226,44280060,15,America/New_York,EDT,False,False,USD,-0.63,us_market,"Enveric Biosciences, Inc.",NCM,REGULAR,4,4.0251284,2.01 - 2.14,1.99,2.09,2.1,11,8,finmb_650902272,NasdaqCM,"Enveric Biosciences, Inc.",USD,1124845,409050,0.59010005,0.39871624,1.48 - 15.04,-12.9699,-0.86236036,1.48,15.04,1574640000,1621323004,1628765940,0,1629115200,-14400000,,,,15.04,1.48,1.9122,2.547,1.12M,409.05k,21.39M,,16.85M,25.53%,5.24%,1.06M,0.39,5.55%,4.95%,536.9k,,,,,,0.00%,"Nov 24, 2019","Apr 22, 2008",,,"Dec 30, 2020","Mar 30, 2021",0.00%,0.00%,-55.15%,-110.38%,,,,,,-9.02M,,,22.66M,1.06,,,37.36,,-6.16M,-2.91M,Value,34103,Healthcare,2,"Enveric Biosciences, Inc., a pharmaceutical company, engages in developing various cannabinoid medicines for cancer care. It has a pipeline of development programs for radiodermatitis, glioblastoma multiforme, pruritus, rashes, and dry skin and chemotherapy-induced neuropathy. The company is headquartered in Naples, Florida.",Naples,239 302 1707,FL,1609372800,United States,http://www.enveric.com,86400,4851 Tamiami Trail North,Biotechnology,Suite 200
t-2,ENVB,-3482013.0,21390300,174083,,-565335,,-565335,489834,0,-489834,-489834,,-75501.0,,,,0,0,489834,0,-75501,,-565335,-565335,,,,-3482013.0,,,,,,,,,,,,,-414473.0,-44143.0,227500.0,52116.0,227500.0,-100495.0,65747.0,-393742.0,120872.0,783520.0,-33926.0,,en-US,US,EQUITY,True,Nasdaq Real Time Price,2.0701,1630509439,0.08010006,2.05,2.14,2.01,796799,-3.2858732,1.9122223,0.1578778,0.08256248,2.5469565,-0.47685647,-0.187226,44280060,15,America/New_York,EDT,False,False,USD,-0.63,us_market,"Enveric Biosciences, Inc.",NCM,REGULAR,4,4.0251284,2.01 - 2.14,1.99,2.09,2.1,11,8,finmb_650902272,NasdaqCM,"Enveric Biosciences, Inc.",USD,1124845,409050,0.59010005,0.39871624,1.48 - 15.04,-12.9699,-0.86236036,1.48,15.04,1574640000,1621323004,1628765940,0,1629115200,-14400000,,,,15.04,1.48,1.9122,2.547,1.12M,409.05k,21.39M,,16.85M,25.53%,5.24%,1.06M,0.39,5.55%,4.95%,536.9k,,,,,,0.00%,"Nov 24, 2019","Apr 22, 2008",,,"Dec 30, 2020","Mar 30, 2021",0.00%,0.00%,-55.15%,-110.38%,,,,,,-9.02M,,,22.66M,1.06,,,37.36,,-6.16M,-2.91M,Value,34103,Healthcare,2,"Enveric Biosciences, Inc., a pharmaceutical company, engages in developing various cannabinoid medicines for cancer care. It has a pipeline of development programs for radiodermatitis, glioblastoma multiforme, pruritus, rashes, and dry skin and chemotherapy-induced neuropathy. The company is headquartered in Naples, Florida.",Naples,239 302 1707,FL,1609372800,United States,http://www.enveric.com,86400,4851 Tamiami Trail North,Biotechnology,Suite 200
t-3,ENVB,-3482013.0,21390300,174083,,-818391,,-818391,767508,0,-767508,-767508,,-50883.0,,,,0,0,767508,0,-50883,,-818391,-818391,,3364109.0,4036775.0,-3482013.0,554762.0,,-6811733.0,,-34389.0,441393.0,4036775.0,-34389.0,554762.0,1405272.0,21343.0,50553.0,422105.0,-44143.0,492500.0,-2528.0,227500.0,166082.0,24716.0,-351134.0,120872.0,-201890.0,492500.0,-3482013.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,2.0701,1630509439,0.08010006,2.05,2.14,2.01,796799,-3.2858732,1.9122223,0.1578778,0.08256248,2.5469565,-0.47685647,-0.187226,44280060,15,America/New_York,EDT,False,False,USD,-0.63,us_market,"Enveric Biosciences, Inc.",NCM,REGULAR,4,4.0251284,2.01 - 2.14,1.99,2.09,2.1,11,8,finmb_650902272,NasdaqCM,"Enveric Biosciences, Inc.",USD,1124845,409050,0.59010005,0.39871624,1.48 - 15.04,-12.9699,-0.86236036,1.48,15.04,1574640000,1621323004,1628765940,0,1629115200,-14400000,,,,15.04,1.48,1.9122,2.547,1.12M,409.05k,21.39M,,16.85M,25.53%,5.24%,1.06M,0.39,5.55%,4.95%,536.9k,,,,,,0.00%,"Nov 24, 2019","Apr 22, 2008",,,"Dec 30, 2020","Mar 30, 2021",0.00%,0.00%,-55.15%,-110.38%,,,,,,-9.02M,,,22.66M,1.06,,,37.36,,-6.16M,-2.91M,Value,34103,Healthcare,2,"Enveric Biosciences, Inc., a pharmaceutical company, engages in developing various cannabinoid medicines for cancer care. It has a pipeline of development programs for radiodermatitis, glioblastoma multiforme, pruritus, rashes, and dry skin and chemotherapy-induced neuropathy. The company is headquartered in Naples, Florida.",Naples,239 302 1707,FL,1609372800,United States,http://www.enveric.com,86400,4851 Tamiami Trail North,Biotechnology,Suite 200
